Skip to main content

Table 1 Patients characteristics and results

From: Value and price of ventilator-associated pneumonia surveillance as a quality indicator

Patients ventilated >48 hours (n)

169

Male:female

110:59

Medical ICU (n)

49

Surgical ICU (n)

55

Neuro-surgical ICU (n)

29

Cardio-thoracic ICU (n)

36

Age, years, median (range)

60 (21-84)

APACHE II score, median (range)

19 (12-36)

Length of ICU stay, days, median (range)

12 (2-103)

Ventilator days, median (range)

7 (2-91)

VAP, definite (n)*

15

VAP, probable (n)†

12

Definite VAP per 1,000 ventilator days (n)

7.5

Percentage patients with definite VAP (%)

8.9%

ICU mortality, n (%)

34 (20%)

Mortality in patients with definite VAP, n (%)

2 (13%)

  1. *Defined as based on Centers for Disease Control and Prevention criteria [4], with a new and persistent infiltrate on chest X-ray, a positive culture in trachea-aspirate or broncho-alveolar lavage, occurrence of purulent sputum, fever and/or leucocytosis or leucopenia as obligatory features. †Defined as based on Centers for Disease Control and Prevention criteria [4]; all the same circumstances as above except a positive culture as the required parameters. VAP, ventilator-associated pneumonia.
Back to article page

Critical Care

ISSN: 1364-8535